Innovative Approach to Produce Shatter Resistant Auto-Injector Formula Containers
Award amount
$167,469Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Defense
- Branch
- Office for Chemical and Biological Defense
- Recipient company
- RX BANDZ, INC.
- Proposal award date
- 2021-05-12
- Contract end date
- 2021-11-12
- UEI
- DXRED7S6FVE9
- Solicitation number
- 20.2
- Topic code
- CBD202-003
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Shelf-life Extension for Emergency Medication
- Continue, Expand, and Refine Research and Development of a Hydromorphone Autoinjector
- Stop The Bleed - Save the Warfighter! : Intramuscular Auto-Injector Delivery of Tranexamic Acid (TXA) on the Battlefield
- Extended Utilization of Lifesaving Medications via Autoinjector
- Auto Injector Administration of Ketamine for Critically Injured Airmen
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Austere environment, durable, safe, glass equivalent auto injector container technology
- Austere environment, durable, safe, glass equivalent auto injector container technology
Research funding history
12 SBIR/STTR records share this UEI (2020–2023). Reported award amounts total $6,990,569. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Defense